The phase 3 VALOR trial shows that brepocitinib significantly improves skin disease, muscle strength, and functional disability in adults with dermatomyositis. As the first modern targeted therapy to demonstrate positive results, brepocitinib may transform treatment options while reducing steroid reliance.
DERMATOLOGYIMMUNOLOGYTRIALS < class="penci-entry-title entry-title grid-title penci_grid_title">Brepocitinib may emerge as the first targeted treatment option for dermatomyositis.